Brief: UCB's Kygevvi Approved In The EU As First And Only Treatment For Thymidine Kinase 2 Deficiency

UCB SA

31/03/2026 06:09

March 31 (Reuters) - Ucb SA UCB.BR:

EUROPEAN COMMISSION APPROVES KYGEVVI (DOXECITINE AND DOXRIBTIMINE) AS FIRST AND ONLY TREATMENT FOR THYMIDINE KINASE 2 DEFICIENCY (TK2D)

USE OF KYGEVVI LED TO IMPROVEMENTS IN MOTOR FUNCTION, AS WELL AS A REDUCTION IN USE OF VENTILATORY AND FEEDING SUPPORT

Source text: Here for full press release

Further company coverage: UCB.BR

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))